| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 161.64 | 37.1% | 77.4% |
| Total Income | 161.64 | 37.1% | 77.3% |
| Expenditure | 156.68 | 35.8% | 72.9% |
| PBT | 4.97 | 94.9% | 887.1% |
| Net Profit | 4.17 | 119.7% | 729.2% |
| OPM | 3.69% | 0.89pp | 3.94pp |
| NPM | 2.58% | 0.97pp | 2.03pp |
| EPS | 0.96 | 118.2% | 638.5% |
Syschem India Ltd. Announces Q3 Results with 189.84% YoY Growth and Approves Expansion of Existing Plant Units
02 Feb 2026 · 2 Feb, 3:30 pm
Summary
Syschem India Ltd. has announced its Q3 results with a significant YoY growth of 189.84%. The company's Board of Directors has also approved the expansion of existing plant units, including the addition of a new manufacturing unit for Amoxicillin and Ampicillin, and further expansion of the existing CDF unit. The expansion also includes the strengthening of environmental compliance with the expansion of the Effluent Treatment Plant (ETP) and Multi-Effect Evaporator (MEE).
Key Highlights
- 1
189.84% YoY growth in Q3 results
- 2
Expansion of existing plant units
- 3
Addition of a new manufacturing unit for Amoxicillin and Ampicillin
- 4
Further expansion of the existing CDF unit
- 5
Expansion of Effluent Treatment Plant (ETP) and Multi-Effect Evaporator (MEE)
Management Comments
Shikha Kataria
In view of the tremendous market response to the Company’s products, the Board has considered and approved the expansion of its existing plant units. The expansion includes the addition of a new manufacturing unit for Amoxicillin and Ampicillin, along with further expansion of the existing CDF unit comprising Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. I Digitally signed S h I kh a by Shikha Kataria Date: 2026.02.02 Ka ta ria 15:24:43 +05'30!
Informational and educational content only. Not investment advice.